335 related articles for article (PubMed ID: 27868275)
1. Effectiveness and safety of drugs used for stroke prevention in a cohort of non-valvular atrial fibrillation patients from a primary care electronic database.
Giner-Soriano M; Roso-Llorach A; Vedia Urgell C; Castells X; Capellà D; Ferreira-González I; Elorza-Ricart JM; Casajuana M; Troncoso Mariño A; Diògene E; Bolíbar B; Violan C; Morros R
Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):97-107. PubMed ID: 27868275
[TBL] [Abstract][Full Text] [Related]
2. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study.
Gieling EM; van den Ham HA; van Onzenoort H; Bos J; Kramers C; de Boer A; de Vries F; Burden AM
Br J Clin Pharmacol; 2017 Aug; 83(8):1844-1859. PubMed ID: 28205318
[TBL] [Abstract][Full Text] [Related]
3. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database.
Giner-Soriano M; Vedia Urgell C; Roso-Llorach A; Morros R; Capellà D; Castells X; Ferreira-González I; Troncoso Mariño A; Diògene E; Elorza JM; Casajuana M; Bolíbar B; Violan C
BMJ Open; 2016 Jan; 6(1):e010144. PubMed ID: 26823179
[TBL] [Abstract][Full Text] [Related]
5. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement.
Abdul-Jawad Altisent O; Durand E; Muñoz-García AJ; Nombela-Franco L; Cheema A; Kefer J; Gutierrez E; Benítez LM; Amat-Santos IJ; Serra V; Eltchaninoff H; Alnasser SM; Elízaga J; Dager A; García Del Blanco B; Ortas-Nadal Mdel R; Marsal JR; Campelo-Parada F; Regueiro A; Del Trigo M; Dumont E; Puri R; Rodés-Cabau J
JACC Cardiovasc Interv; 2016 Aug; 9(16):1706-17. PubMed ID: 27539691
[TBL] [Abstract][Full Text] [Related]
6. Residential medication management reviews of antithrombotic therapy in aged care residents with atrial fibrillation: assessment of stroke and bleeding risk.
Nishtala PS; Castelino RL; Peterson GM; Hannan PJ; Salahudeen MS
J Clin Pharm Ther; 2016 Jun; 41(3):279-84. PubMed ID: 27062272
[TBL] [Abstract][Full Text] [Related]
7. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.
Lemesle G; Ducrocq G; Elbez Y; Van Belle E; Goto S; Cannon CP; Bauters C; Bhatt DL; Steg PG;
Clin Cardiol; 2017 Oct; 40(10):932-939. PubMed ID: 28692742
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study.
Loo SY; Coulombe J; Dell'Aniello S; Brophy JM; Suissa S; Renoux C
BMJ Open; 2018 Jan; 8(1):e019638. PubMed ID: 29371284
[TBL] [Abstract][Full Text] [Related]
9. Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program.
McIntyre WF; Conen D; Olshansky B; Halperin JL; Hayek E; Huisman MV; Lip GYH; Lu S; Healey JS
Clin Cardiol; 2018 Jun; 41(6):744-751. PubMed ID: 29546729
[TBL] [Abstract][Full Text] [Related]
10. Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists.
Gieling E; de Vries F; Williams R; van Onzenoort HAW; de Boer A; Ten Cate V; Kramers C; Burden A
Int J Clin Pharm; 2019 Dec; 41(6):1536-1544. PubMed ID: 31595448
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
[TBL] [Abstract][Full Text] [Related]
12. Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.
Vlacho B; Giner-Soriano M; Zabaleta-Del-Olmo E; Roso-Llorach A; García-Sangenís A; Morros-Pedrós R
Eur J Clin Pharmacol; 2017 Oct; 73(10):1323-1330. PubMed ID: 28725983
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Adherence to Guideline-Directed Antithrombotic Therapy for Atrial Fibrillation at Hospital Discharge.
Dupree L; DeLosSantos M; Smotherman C
J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):502-508. PubMed ID: 29806486
[TBL] [Abstract][Full Text] [Related]
14. Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study.
Renoux C; Coulombe J; Suissa S
BMC Cardiovasc Disord; 2016 May; 16():84. PubMed ID: 27160254
[TBL] [Abstract][Full Text] [Related]
15. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
Van Der Meersch H; De Bacquer D; De Vriese AS
Am Heart J; 2017 Feb; 184():37-46. PubMed ID: 27892885
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
[TBL] [Abstract][Full Text] [Related]
17. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial.
Flaker GC; Eikelboom JW; Shestakovska O; Connolly SJ; Kaatz S; Budaj A; Husted S; Yusuf S; Lip GY; Hart RG
Stroke; 2012 Dec; 43(12):3291-7. PubMed ID: 23033347
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice.
Coleman CI; Peacock WF; Antz M
Heart Lung Circ; 2018 Mar; 27(3):390-393. PubMed ID: 28528780
[TBL] [Abstract][Full Text] [Related]
19. Atrial fibrillation in New Zealand primary care: Prevalence, risk factors for stroke and the management of thromboembolic risk.
Tomlin AM; Lloyd HS; Tilyard MW
Eur J Prev Cardiol; 2017 Feb; 24(3):311-319. PubMed ID: 27798365
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
